ГЕМАТУРИЯ В ПРАКТИКЕ ТЕРАПЕВТА
Аннотация
В настоящей публикации рассматривается диагностическая тактика при выявлении у пациента макрогематурии, с поиском причин и формулированием соответствующих рекомендаций.
Литература
Truhan DI, Bagisheva NV, Goloshubina VV, Konshu NV. Differencialnyj diagnoz mochevogo sindroma: jeritrociturija. [Differential diagnosis urinary syndrome: erythrocyteuria]. Mezhdunarodnyj zhurnal prikladnyh i fundamentalnyh issledovanij. 2017;2-1:28-32. (Russian).
Moreno JA, Sevillano Á, Gutiérrez E, Guerrero-Hue M, Vázquez-Carballo C, Yuste C, Herencia C, GarcíaCaballero C, Praga M, Egido J. Glomerular Hematuria: Cause or Consequence of Renal Inflammation? International Journal of Molecular Sciences. 2019;20(9):2205. http://doi.org/10.3390/ijms20092205.
Polito MG, de Moura LAR, Kirsztajn GM. An overview on frequency of renal biopsy diagnosis in Brazil: Clinical and pathological patterns based on 9617 native kidney biopsies. Nephrology Dialysis Transplantation. 2010;25(2):490–496. http://doi.org/10.1093/ndt/gfp355.
Brodsky S, Eikelboom J, Hebert LA. AnticoagulantRelated Nephropathy. Journal of the American Society of Nephrology. 2018;29(12):2787–2793. http://doi.org/10.1681/asn.2018070741.
Orlandi PF, Fujii N, Roy J, Chen HY, Lee Hamm L, Sondheimer JH, He J, Fischer MJ, Rincon-Choles H, Krishnan G, Townsend R, Shafi T, Hsu CY, Kusek JW, Daugirdas JT, Feldman HI. Hematuria as a risk factor for progression of chronic kidney disease and death: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. BMC Nephrology. 2018;19(1):150. http://doi.org/10.1186/s12882-018-0951-0.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Kikuchi M, Shobu Y. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. Clinical and Experimental Nephrology. 2018;22(2):299–308. http://doi.org/10.1007/s10157-017-1447-0.
Moreno JA, Martín-Cleary C, Gutiérrez E, Toldos O, Blanco-Colio LM, Praga M, Ortiz A, Egido J. AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences. Clinical Journal of the American Society of Nephrology. 2012;7(1):175–184. http://doi.org/10.2215/cjn.01970211.
Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. Journal of Pathology. 2018:244(3):296–310. http://doi.org/10.1186/s12882-018-0951-0.
Immenschuh S, Vijayan V, Janciauskiene S, Gueler F. Heme as a Target for Therapeutic Interventions. Frontiers in Pharmacology. 2017;8:146. http://doi.org/10.3389/fphar.2017.00146.
Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH. Management and treatment of glomerular diseases (part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2019;95:268–280.
